Heart Failure Clinical Trial

Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

Summary

The goal of this multicenter observational clinical trial is to evaluate the safety and effectiveness of the Cardiohelp System for VA-ECMO in children with cardiac failure. The main question[s] it aims to answer are:

What is the safety and effectiveness of the Cardiohelp device for pediatric ECMO?
What are the optimal performance specifications of the Cardiohelp device in children? Should the Cardiohelp device be FDA-cleared for children?

Children who are receiving the Cardiohelp device will be approached and consented to participate if interested. Participants will undergo a standardized data collection to estimate survival to 30 days and the prevalence of serious adverse events like stroke, bleeding, and hemolysis.

Outcomes will be compared to performance goals (PG) derived from the ECMO literature.

Funding Source -- FDA OOPD (Office of Orphan Product Development)

View Full Description

Full Description

This is a multicenter clinical trial to evaluate the safety and effectiveness of the Cardiohelp System for up to 30 days of support in children with severe cardiac failure. Despite more than 50 years of use and significant mortality, no standalone ECMO device has ever been FDA-cleared for ECMO. All ECMO use in children is off-label and this may explain why there is significant center-based variation in ECMO use that is not evidence driven. This study seeks to change that by collecting systematic safety and effectiveness data on a single standardized ECMO circuit (Cardiohelp Device). The goal is to provide the data necessary to secure FDA clearance of the first pediatric ECMO system, to determine the optimal performance range of the Cardiohelp device in infants and children, and to provide the FDA with a predicate device to support FDA clearance of other ECMO systems.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age 0 to 16 years of age
Body weight 3 to 80 kilograms
VA-ECMO use for primary cardiac failure using the Cardiohelp system.
First ECMO run during any hospitalization
Written informed consent from the parent or legally authorized representative.

Exclusion Criteria:Children must not meet any of the following exclusion criteria within 48 hours prior to device implant:

Gestational Age <37 weeks
Bleeding or coagulopathy that is a contraindication to anticoagulation
Irreversible renal, hepatic or lung failure
Stroke or uncertain neurological status within the past 30 days
Severely malnourished
Use of an ECMO system other than the Cardiohelp
VV-ECMO or ECMO for primary respiratory failure
Goals of patient to focus on comfort measures only.
Failure to separate from cardiopulmonary bypass

Study is for people with:

Heart Failure

Estimated Enrollment:

50

Study ID:

NCT06080074

Recruitment Status:

Not yet recruiting

Sponsor:

Stanford University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Cuimc/Nyph
New York New York, 10032, United States More Info
Eva Cheung, MD
Contact

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Estimated Enrollment:

50

Study ID:

NCT06080074

Recruitment Status:

Not yet recruiting

Sponsor:


Stanford University

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.